90 related articles for article (PubMed ID: 18024630)
1. Risk, cure and complications in advanced hodgkin disease.
Horning SJ
Hematology Am Soc Hematol Educ Program; 2007; ():197-203. PubMed ID: 18024630
[TBL] [Abstract][Full Text] [Related]
2. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
[TBL] [Abstract][Full Text] [Related]
3. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
Diehl V; Franklin J; Pfreundschuh M; Lathan B; Paulus U; Hasenclever D; Tesch H; Herrmann R; Dörken B; Müller-Hermelink HK; Dühmke E; Loeffler M;
N Engl J Med; 2003 Jun; 348(24):2386-95. PubMed ID: 12802024
[TBL] [Abstract][Full Text] [Related]
4. Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma.
Bauer K; Skoetz N; Monsef I; Engert A; Brillant C
Cochrane Database Syst Rev; 2011 Aug; (8):CD007941. PubMed ID: 21833963
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study.
Vijenthira A; Chan K; Cheung MC; Prica A
Lancet Haematol; 2020 Feb; 7(2):e146-e156. PubMed ID: 31948928
[TBL] [Abstract][Full Text] [Related]
6. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.
Gallamini A; Tarella C; Viviani S; Rossi A; Patti C; Mulé A; Picardi M; Romano A; Cantonetti M; La Nasa G; Trentin L; Bolis S; Rapezzi D; Battistini R; Gottardi D; Gavarotti P; Corradini P; Cimminiello M; Schiavotto C; Parvis G; Zanotti R; Gini G; Ferreri AJM; Viero P; Miglino M; Billio A; Avigdor A; Biggi A; Fallanca F; Ficola U; Gregianin M; Chiaravalloti A; Prosperini G; Bergesio F; Chauvie S; Pavoni C; Gianni AM; Rambaldi A
J Clin Oncol; 2018 Feb; 36(5):454-462. PubMed ID: 29360414
[TBL] [Abstract][Full Text] [Related]
7. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly).
Ballova V; Rüffer JU; Haverkamp H; Pfistner B; Müller-Hermelink HK; Dühmke E; Worst P; Wilhelmy M; Naumann R; Hentrich M; Eich HT; Josting A; Löffler M; Diehl V; Engert A
Ann Oncol; 2005 Jan; 16(1):124-31. PubMed ID: 15598949
[TBL] [Abstract][Full Text] [Related]
8. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
[TBL] [Abstract][Full Text] [Related]
9. Standard therapy of advanced Hodgkin lymphoma.
Kuruvilla J
Hematology Am Soc Hematol Educ Program; 2009; ():497-506. PubMed ID: 20008235
[TBL] [Abstract][Full Text] [Related]
10. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
[TBL] [Abstract][Full Text] [Related]
11. What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?
Hehn ST; Miller TP
Curr Hematol Rep; 2004 Jan; 3(1):17-26. PubMed ID: 14695845
[TBL] [Abstract][Full Text] [Related]
12. Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma.
Reid JH; Marini BL; Nachar VR; Brown AM; Devata S; Perissinotti AJ
Crit Rev Oncol Hematol; 2020 Apr; 148():102897. PubMed ID: 32109715
[TBL] [Abstract][Full Text] [Related]
13. Does interim PET increase the value of ABVD in advanced-stage Hodgkin lymphoma?
Gallamini A; Kostakoglu L
Ann Oncol; 2015 Jun; 26(6):1045-1047. PubMed ID: 26003616
[No Abstract] [Full Text] [Related]
14. Treatment of newly diagnosed advanced stage Hodgkin lymphoma.
Uhm J; Kuruvilla J
Blood Rev; 2012 Jul; 26(4):167-74. PubMed ID: 22542250
[TBL] [Abstract][Full Text] [Related]
15. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
Canellos GP
Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
[TBL] [Abstract][Full Text] [Related]
16. Evolving approaches to primary treatment of Hodgkin lymphoma.
Connors JM
Hematology Am Soc Hematol Educ Program; 2005; ():239-44. PubMed ID: 16304387
[TBL] [Abstract][Full Text] [Related]
17. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group.
Eich HT; Staar S; Gossmann A; Hansemann K; Skripnitchenko R; Kocher M; Semrau R; Engert A; Josting A; Franklin J; Krug B; Diehl V; Müller RP;
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1121-7. PubMed ID: 15001253
[TBL] [Abstract][Full Text] [Related]
18. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
Brosteanu O; Hasenclever D; Loeffler M; Diehl V;
Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867
[TBL] [Abstract][Full Text] [Related]
19. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
[TBL] [Abstract][Full Text] [Related]
20. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C
J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
